Public Policy Trends in Drug Pricing and Reimbursement in the European Community Heinz Redwood OriginalPaper 25 November 2012 Pages: 3 - 10
The National Health Service Pharmaceuticals Market David G. Green Short Communication 25 November 2012 Pages: 11 - 14
Recent Public Policies in The Netherlands to Control Pharmaceutical Pricing and Reimbursement Henk Rigter OriginalPaper 25 November 2012 Pages: 15 - 21
The Impact of Recent Legislative Change in Germany Frank E. MünnichKevin Sullivan OriginalPaper 25 November 2012 Pages: 22 - 27
New Developments in Pricing and Drug Reimbursement in France Alain PelcJean-Philippe Castan OriginalPaper 25 November 2012 Pages: 28 - 35
The Pricing and Reimbursement of Pharmaceuticals Adrian Towse Discussant’s Summary 25 November 2012 Pages: 36 - 38
The Emerging Government Requirement for Economic Evaluation of Pharmaceuticals Michael Drummond OriginalPaper 25 November 2012 Pages: 42 - 50
Pricing and Reimbursement of Pharmaceuticals in Sweden Bengt Jönsson OriginalPaper 25 November 2012 Pages: 51 - 60
Balancing Costs, Efficacy, and Side Effects Jerry Avorn OriginalPaper 25 November 2012 Pages: 63 - 66
Pricing, Regulation, and Competitiveness Lacy Glenn Thomas III OriginalPaper 25 November 2012 Pages: 67 - 70
The Canadian Patented Medicine Prices Review Board Sheila R. Shulman OriginalPaper 25 November 2012 Pages: 71 - 79
The Changing Environment for US Pharmaceuticals Paul R. Meyer OriginalPaper 25 November 2012 Pages: 80 - 84
